Logo

Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

Share this

Boehringer Ingelheim Collaborates with PureTech to Develop Immuno-Oncology Candidates for Immune Modulation

Shots:

  • PureTech to receive $26M as an upfront including research funding & preclinical milestone- $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after it enters to development stage by utilizing PureTech’s lymphatic targeting technology
  • The focus of the collaboration is to develop immuno-oncology candidates for gastrointestinal (GI) cancers administered directly to the gut lymphatics to potentially tune systemic and local immunity
  • PureTech’s lymphatic targeting technology is designed to enable the transport of drug directly into the lymphatic system when administered orally targeting cancer- inflammatory and autoimmune diseases

Ref: Puretech | Image: Pinterest

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions